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Abstract: Recent studies focused on the pharmacology and feasibility of herbal compounds as a
potential strategy to target a variety of human diseases ranging from metabolic to brain disorders.
Accordingly, bioactive ingredients which are found within a variety of herbal compounds are reported
to produce both neuroprotective and psychotropic activities which may help to combat mental
disorders such as depression, anxiety, sleep disturbances and cognitive alterations. In the present
manuscript, we focus on three herbs which appear effective in mitigating anxiety or depression with
favourable risk-benefit profiles, namely Scutellaria baicalensis (S. baicalensis), Hericium erinaceus
(H. erinaceus) and Rhodiola rosea (R. rosea). These three traditional folk medicinal herbs target the
main biochemical events that are implicated in mental disorders, mimicking, to some extent, the
mechanisms of action of conventional antidepressants and mood stabilizers with a wide margin
of tolerability. In detail, they rescue alterations in neurotransmitter and neuro-endocrine systems,
stimulate neurogenesis and the synthesis of neurotrophic factors, and they counteract oxidative stress,
mitochondrial dysfunction and inflammation. Albeit the encouraging results that emerge from both
experimental and clinical evidence, further studies are needed to confirm and better understand the
mental-health promoting, and specifically, the antidepressant effects of these herbs.
Keywords: phytochemicals; depression; anxiety; monoamines; neuroprotection; neurogenesis;
neurotrophic factors; antioxidant; anti-inflammatory
1. Introduction
A growing number of people worldwide suffer from age- or stress-related mental disorders
such as depression, anxiety and insomnia. Since many conventional medications possess either
side effects or limited efficacy, many patients increasingly prefer herbal compounds for such mood
symptoms relief [1]. Accordingly, recent investigations have focused on the psychopharmacology
of naturally-occurring compounds as a potential strategy to target mental disorders. Wide evidence
indicates that bioactive ingredients found within a variety of phytochemical compounds are endowed
with multiple, yet intricate, psychotropic activities which may help to combat depression, anxiety,
sleep disorders and cognitive alterations [2]. Several phytochemicals are reported to produce mental
benefits that are comparable to standard anxiolytics and antidepressants in the absence of overt adverse
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effects [1,2]. As such, they appear as an optimal, first-choice therapy in mild-to-moderate depressive
disorders. Furthermore, some herbal extracts may be also combined or enriched with conventional
antidepressants and mood stabilizers to alleviate some of their common side effects while potentiating
their efficacy [3,4].
In the present manuscript we focus on three neuroprotective herbs which appear effective in
mitigating anxiety or depression with favourable risk-benefit profiles, namely Scutellaria baicalensis
(S. baicalensis) [5–9], Hericium erinaceus (H. erinaceus) [10–14] and Rhodiola rosea (R. rosea) [15–20]. We
chose these specific herbs in order to analyse both their overlapping and complementary properties, posing
the provocative issue of whether their combined administration may yield synergistic antidepressant-like
effects. The general health-promoting effects of S. baicalensis, H. erinaceus and R. rosea in humans and
animals are mainly attributable to anti-inflammatory and antioxidant properties [6–8,16–19,21–31].
At a first glance, the mechanisms of action of these herbal compounds in mental diseases
appear puzzling and often overlapping. The bioactive ingredients found within S. baicalensis,
H. erinaceus and R. rosea target the main biochemical events which are implicated in psychiatric
conditions [32–34] mimicking at some extent the mechanisms of action of conventional antidepressants
and mood stabilizers in the absence of serious adverse effects [5,10,13,15,20,35,36] (Figure 1). Far
from being the aim of the present manuscript is an attempt to deal with the neurobiology of
depression, which is a complex, multifactorial disorder [33], here we limit to reviewing and discussing
potential biochemical and molecular mechanisms through which the abovementioned compounds
produce anxiolytic/antidepressant-like effects. In detail, bioactive compounds within S. baicalensis,
H. erinaceus and R. rosea rescue alterations in monoamine and GABA neurotransmission, and they
stimulate neurogenesis and the synthesis of neurotrophic factors while counteracting oxidative
stress, mitochondrial dysfunction and inflammation (Figure 1) [5–15,20]. These herbs also modulate
neuro-immune and neuro-endocrine functions by targeting hypothalamic-pituitary-adrenal (HPA)
axis hyper-activation, which is implicated in mental disorders (Figure 1) [1,19,33]. Nonetheless, at
a closer examination, each plant possesses specific effects by acting on different neurotransmitter
systems and molecular pathways. After briefly summarizing the main herbal-related neuroprotective
mechanisms which may be relevant for depressive disorders, we move to discuss evidence centred
on the anxiolytic/antidepressant potential of each herb, as assessed specifically in experimental and
clinical studies.
The still limited, although encouraging, results which emerge from both experimental and clinical
studies underline the need for further investigations aimed at dissecting the fine molecular mechanisms
of action as well as the safety and pharmacokinetic profiles of these herbal compounds.
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Figure 1. A general view on the mechanisms of action of S. baicalensis, H. herinaceum and R. rosea 
against the main biological pathways that are altered in depression and depressive-like behavior 
(yellowish box). Hypotheses on the neurobiology of depression and anxiety are largely based on 
dysregulations of i) neurotransmitter systems, including GABA and GABAA receptors [8], as well as 
monoamines (dopamine, norepinephrine and serotonin) [9]; ii) hypothalamic-pituitary-adrenal 
(HPA) axis consisting of an abnormal release of corticotropin-releasing factor (CRH), 
adrenocorticotropin (ACTH) secretion from the anterior pituitary, abnormal secretion of 
glucocorticoids (cortisol in humans and corticosterone in rodents), activation of phosphorylated c-Jun 
kinase (pJNK), and aberrant negative feedback HPA axis [9]. iii) impaired neurotrophic mechanisms 
consisting of low expression of nerve growth factor (NGF) and brain-derived neurotrophic factor 
(BDNF), impaired neurogenesis and plasticity [9]; iv) chronic oxidative stress and neuroinflammation 
[10]. Black T-shaped lines indicate inhibition. Red bold arrows indicate downregulation or 
hyperactivation. Red thin arrows indicate sequential molecular events. 
2. S. baicalensis, H. erinaceus and R. rosea: Toxicology and Neuroprotective Effects which may be 
Relevant for their Antidepressant Potential.  
S. baicalensis, H. erinaceus and R. rosea are folk traditional medicinal herbs that gained increasing 
popularity for their health-promoting properties including antitumor, hepatoprotective, 
antimicrobial, anti-inflammatory, anti-hyperlipidemic, antidiabetic, cardio-protective, neurotrophic 
and neuroprotective effects [5,10,15,16,35,37–47]. In the brain, the beneficial effects of each herb are 
due to different bioactive compounds, some of which are able to cross the blood-brain-barrier (BBB). 
For S. baicalensis these correspond to two major flavonoids, namely baicalin (glucuronide) and 
baicalein (aglycon), being purified from the plant’s dry roots (Scutellariae radix) [48]. H. erinaceus 
possesses three main classes of bioactive compounds, namely polysaccharides, hericenones and 
erinacines, with the first two being extracted from the fruit bodies and the latter from the mycelia. 
Despite the widely reported beneficial effects of these H. erinaceus bioactive ingredients in the brain, 
to date only erinacines have been documented to cross the BBB [49]. Eventually, the main bioactive 
Figure 1. A general view on the mechanisms of action of S. baicalensis, H. herinaceum and R. rosea
against the main biological pathways that are altered in depression and depressive-like behavior
(yellowish box). Hypotheses on the neurobiology of depression and anxiety are largely based on
dysregulations of (i) neurotransmitter systems, including GABA and GABAA receptors [8], as well as
monoamines (dopamine, norepinephrine and serotonin) [9]; (ii) hypothalamic-pituitary-adrenal (HPA)
axis consisting of an abnormal release of corticotropin-releasing factor (CRH), adrenocorticotropin
(ACTH) secretion from the anterior pituitary, abnormal secretion of glucocorticoids (cortisol in humans
nd corticosterone in rodents), activation of phosphorylated c-Jun kinase (pJNK), and aberrant negative
feedback HPA axis [9]. (iii) imp ired neuro rophic m chanisms consisting of low ex ression of nerve
growth factor (NGF) and brain-deriv d neurotrophic factor (BDNF), impai ed neurogenesis and
plasticity [9]; (iv) chronic oxidativ stress and neuroinflammation [10]. Black T-shaped lines indi ate
inhibition. Red bold arrows indicate downregulation or hyperactivation. Red thin arrows indicate
sequential molecular eve ts.
2. S. baicalensis, H. erinaceus and R. rosea: Toxicology and Neuroprotective Effects which may be
Relevant for their Antidepressant Potential
S. baicalens s, H. erinaceus and R. rosea are folk traditional medicinal herbs that gained
increasing popularity for their health-promoting properties including antitumor, hepatoprotective,
antimicrobial, anti-inflammatory, anti-hyperlipidemic, antidiabetic, cardio-protective, neurotrophic
and neuroprotective effects [5,10,15,16,35,37–47]. In the brain, the beneficial effects of each herb are due
to different bioactive compounds, some of which are able to cross the blood-brain-barrier (BBB). For
S. baicalensis these correspond to two major flavonoids, namely baicalin (glucuronide) and baicalein
(aglycon), being purified from the plant’s dry roots (Scutellariae radix) [48]. H. erinaceus possesses three
main classes of bioactive compounds, namely polysaccharides, hericenones and erinacines, with the
first two being extracted from the fruit bodies and the latter from the mycelia. Despite the widely
reported beneficial effects of these H. erinaceus bioactive ingredients in the brain, to date only erinacines
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have been documented to cross the BBB [49]. Eventually, the main bioactive compound of R. rosea is
salidroside glycone, which has been detected in the brain tissue as well [29,50,51].
Based on toxicological and clinical studies, S. baicalensis, H. erinaceus and R. rosea are generally
considered to be safe and well tolerated [40,52–63]. In experimental studies, the estimated median
lethal dose (LD50) of some compounds varies according to the extraction method and administration
route [54]. In fact, as reported by pioneer toxicological studies, following subcutaneous injection in
mice, the median lethal dose (LD50) of both S. baicalensis ethanolic extract and isolated baicalin is
6 g/kg [54]. Instead, the LD50 of isolated baicalin following intraperitoneal injection is 3.081 g/kg [54].
More recently, 2.5 g/kg of S. baicalensis ethanol extracts were shown to be safe in rats, though some
reversible inflammatory changes were detected in the liver [55]. Baicalin was shown to inhibit the
proliferation of embryonic stem cells at half maximal inhibitory concentration (IC50) values up to
135.9 mgL, suggesting that it may induce low embryonic toxicity at high concentrations [56]. In
humans, oral intake of S. baicalensis extracts and baicalin at the daily doses of 300 mg and 200–800 mg
respectively, is generally safe and well tolerated [57,58].
As far as it concerns H. erinaceus, the acute oral LD50 of its erinacine-A-enriched mycelia is
higher than 5 g/kg in rats [59]. As shown by sub-chronic toxicology studies, erinacine-A-enriched
H. erinaceus administered daily for 28 days or 13 weeks is safe and not teratogenic at doses up to 3 g/kg
and 2.625 g/kg, respectively, which is nearly 171 times the recommended daily intake for humans
(1.05 g/60 kg of body weight/day) [60,61]. Moreover, H. erinaceus mycelium is not mutagenic in the
bacterial reverse mutation test (Ames test), in vitro chromosome aberration test, and in vivo erythrocyte
micronucleus test [61]. In line with these studies, in rats, no toxicity signs are observed following oral
administration of an H. erinaceus mycelia extract at 2.395 g/kg [49]. In humans, no adverse effects are
reported following oral intake of H. erinaceus extracts at the cumulative dose of 1.650 g/day (of which
80% bulk mycelia, and 20% fruiting body extracts) [62].
Pioneer acute toxicity studies showed that R. rosea possesses low toxicity in rats, with LD50 being
estimated as 3.360 g/kg [63]. However, in more recent toxicological studies on R. rosea-treated mice
and A. salina brine shrimp, neither the LD50 >5.000 g/kg nor the LC50 >1.000 mg/ml exhibited toxic
effects [64]. Salidroside, the main active component of R. rosea is not genotoxic at doses up to 1.5 g/kg
in mice and it does not lead to maternal or embryonic toxicity at 0.125 g/kg in rats [65,66]. In summary,
based on known toxicological data on animal studies, R. rosea is generally evidenced to be safe, with no
acute and chronic toxicity under the experimental conditions at its therapeutic window [53,64]. In line
with this, oral intake of R. rosea at does up to 680 mg/day does not produce any serious adverse effects
in humans [67].
2.1. Common Neuroprotective Effects of S. baicalensis, H. erinaceus and R. rosea
S. baicalensis, H. erinaceus and R. rosea produce neuroprotective effects in models of Parkinson’s
disease (PD) [6,7,12,17,68,69], Alzheimer’s disease (AD) [11,70–79], Huntington disease (HD) [18],
hypoxia/hypo-perfusion/stroke [51,80,81], nerve and brain injury [82,83], glutamate-induced
neurotoxicity [16,75,84], and epilepsy [85–87]. The in vitro and in vivo neuroprotective effects of
these herbal compounds, administered as either full/enriched herbal extracts and/or as single bioactive
ingredients, are largely attributable to antioxidant, mitochondrial-protecting and anti-inflammatory
activities (Figure 2).
In detail, common antioxidant properties of these compounds consist of reducing the levels of
reactive oxygen and nitrogen species (ROS and RNS, respectively), enhancing superoxide dismutase
(SOD), glutathione (GSH), glutathione peroxidase (GSH-Px) and catalase (CAT) activities along with heat
shock proteins 70 (HSP70), heme oxygenase-1 (HO-1) and thioredoxin levels, and eventually, decreasing
lipid peroxidation assessed as reduction of malondialdehyde (MDA) content and lipoxygenase (LPX)
inhibition [6,7,12,17,26–28,69,70,73,75,78,79,81,85–87]. They also counteract mitochondrial alterations,
endoplasmic reticulum (ER) stress, and apoptosis by improving mitochondrial membrane potential
(MMP) depolarization and ATP production while promoting mitophagy and mitochondrial biogenesis,
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and by decreasing the levels of C/EBP Homologous Protein (CHOP), pJNK, p-p38, Bax/Bcl-2 ratio,
caspases 3, 6 and 9, and cytochrome-c release [12,16,51,68,69,71,73,75,77,78,81,83]. Again, S. baicalensis,
H. erinaceus and R. rosea counteract inflammation by decreasing glial cells activation, inducible nitric
oxide synthase (iNOS) and NF- κB levels, as well as the production of pro-inflammatory cytokines
TNF-α and IL-β1 and IL-6 [8,16,29,74,79,83] (Figure 3). Despite being assessed in neurotoxicity models,
these effects may be also key for depressive-related disorders, where oxidative stress, mitochondrial
alterations and inflammation are widely implicated [34]. As a further common effect which is relevant
to both neurodegenerative and mental disorders, these herbs also promote neurogenesis, neuronal
differentiation and the synthesis of neurotrophic factors [8,12,72,74], and they enhance the release of
dopamine (DA), norepinephrine (NE) and serotonin (5-HT), in part by acting as monoamine oxidase
(MAO) inhibitors [6,7,12,88–91]. Nonetheless, at a closer look, each herb also possesses specific effects
which may complementarily contribute to their mood-stabilizing potential beyond neuroprotection.
These effects are discussed in the following section before moving to experimental and clinical studies
on depression.Antioxidants 2020, 9, x FOR PEER REVIEW 5 of 32 
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Figure 2. S. baicalensis: molecular mechanisms underlying neuroprotection and
anxiolytic/antidepressant-like effects. By acting as MAO A/B inhibitors, S. baicalensis and its bioactive
ingredients (mostly baicalin and baicalein) induce monoamine, and mostly DA release. At the same
time, they act as partial, subtype-selective GABAA receptor ligands and also foster the interaction
of GABAA receptors with TrkB to potentiate GABA-induced signaling. By increasing cAMP/pERK
and PI3K/pAKT signaling, they promote the synthesis of neurotrophic factors (BDNF and NGF)
as well as neurogenesis. S. baicalensis promotes anti-inflammatory effects through inhibition of
HMBG1/TLR4/NF-k, AKT/SIRT1/NF-k, and GSK3/NF-k axes. This leads to a reduction in NLRP3 and
proinflammatory cytokines levels. At the same time, S. baicalensis promotes anti-oxidant effects which
are bound to both Ca2+/CAMKII pathway inhibition and mitochondrial protection. By downregulating
SGK1 and FKBP5, S. baicalensis also counteracts alterations in glucocorticoid receptors (GR) associated
with phosphorylation of its crucial serine residues and HPA axis hyperactivity.
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Figure 3. Mechanisms underlying the neuroprotective effects of S. baicalensis, H. erinaceus and
R. rosea. The neuroprotective effects of S. baicalensis, H. erinaceus and R. rosea, administered as
either full/enriched herbal extracts and/or as single bioactive ingredients (central box), are bound to
antioxidant, mitochondrial-protecting, anti-inflammatory, neurotransmitter release-stimulating and
neurotrophic/neurogenic activities. These effects are here represented as pieces of a puzzle where
S. baicalensis, H. erinaceus and R. rosea perfectly fit in the middle. Antioxidant properties of these
compounds consist of reducing the levels of reactive oxygen species (ROS), enhancing superoxide
dismutase (SOD), glutathione (GSH) and catalase (CAT) activities along with heat shock proteins 70
(HSP70), heme oxygenase-1 (HO-1) and thioredoxin (THX) levels, while decreasing lipid peroxidation
(malondialdehyde, MDA, content) and counteracting apoptosis through reduction of Bax, C/EBP
Homologous Protein (CHOP), pJNK, pp38, caspases 3, 6 and 9, and cytochrome-c release. These
effects are closely associated to mitochondrial protection, namely improvement of mitochondrial
membrane potential (MMP) depolarization and ATP production, and concomitant enhancement of
mitophagy and mitochondrial biogenesis via increasing 5’ AMP-activated protein kinase (AMPK),
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α), Nuclear respiratory
factor 1 (NRF1) and Mitochondrial transcription factor A (TFAM). At the same time the three herbs
promote anti-inflammatory effects by decreasing NF-kβ and iNOS enzymes levels while inhibiting
the release of pro-inflammatory cytokines TNF-α, IL-6 and IL-1β. These herbs also target alterations
of neurotransmitter systems, by enhancing the release of monoamine through MAO inhibition,
acetylcholine (Ach) via inhibition of acetylcholine esterase (AchE), and GABA-induced inhibitory
currents by promoting stimulation of GABAA receptors.
2.2. Complementary Effects of S. baicalensis, H. erinaceus and R. rosea
S. baicalensis primarily targets alterations of the DA system, which are implicated in various
neurological and mental disorders, and also in their comorbidity [92]. Immediately after intravenous
administration, total flavonoids from Scutellariae radix are able to cross the BBB, with the striatum
and hippocampus being the most prominent targets [88]. Remarkably, baicalin distributes most
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specifically to the DA system and it induces an increase in DA levels in the rat striatum, hippocampus
and cortex [88,89,93]. Accordingly, recent studies suggest that baicalin and baicalein may induce
beneficial effects in DA-related brain disorders by increasing DA levels in the brain besides protecting
dopaminergic neurons from mitochondrial- and oxidative-related toxicity [6,7,94]. In fact, baicalein
fully prevents 6-OHDA- and MPTP-induced behavioral alterations by preventing reductions of striatal
DA levels, the increase in DOPAC/DA and HVA/DA ratios and the loss of striatal tyrosine hydroxylase
(TH) [6,7]. Similarly, baicalin prevents methamphetamine (METH)-induced alterations, namely the
loss of DA and DA transporter (DAT) in the striatum, which play an important role in the pathogenesis
of mental disorders [94]. Baicalin also ameliorates synaptogenesis and memory-related dysfunctions
which are associated with GABAA receptor downregulation following abnormal stimulation of DA D1
receptors (D1Rs) [95]. In detail, baicalin prevents the reduction of GABAA-induced currents which
occurs following the in vivo administration of exogenous DA and abnormal stimulation of D1Rs [95].
Mechanistically, baicalin fosters the interaction of GABAAR with tyrosine kinase receptor B (TrkB) and
AKT thus reversing the DA-induced decrease in the expression of GABAAR/TrkB/AKT pathway. Thus,
baicalin plays a key role in modulating the GABAergic system. This is supported by the emerging role
of baicalin as a potential anxiolytic by acting as a partial, subtype-selective GABAA receptor ligand [9].
These findings are in line with increasing evidence centered on the neuroprotective and nootropic
action of Scutellariae radix extracts in substance-induced addiction, attention deficit hyperactivity
disorders, depression and anxiety [93,95,96].
H. erinaceus has a prominent effect on neurotrophic factors’ induction and modulation of NE
system. In detail, H. erinaceus bioactive compounds, especially erinacines and hericones, possesses
strong nerve growth factor (NGF)-stimulating properties, showing remarkable neurite outgrowth
activities in various cell lines and in dissociated cells of brain, spinal cord, and retina [40,97–108]. In
detail, H. erinaceus enhances NGF-mediated neurite outgrowth via activation of the Trk/MEK/ERK
and PI3K-Akt signalling pathways [105,106]. Recently, two novel H. erinaceus cyathane diterpenoid
derivatives were shown to promote BDNF expression in vitro, suggesting a common, yet unknown,
upstream target for both NGF and BDNF induction [109]. Intriguingly, in vivo administration of
erinacine A-enriched H. erinaceus extract produces an increase in NGF levels which is detected
specifically within the major NE-producing brainstem nucleus Locus Coeruleus (LC) and within the
hippocampus of rats [90]. Remarkably, such an effect matches the increase in H. erinaceus-induced
NE levels within the LC and hippocampus, suggesting that H. erinaceus, and mostly erinacines, may
modulate neurotrophin-neurotransmitter interactions, especially in the LC-hippocampal axis. This is
key since NE-LC neurons are critically involved in stress-response, depression and sleep disturbances;
in fact, different stress-related molecular changes related to the LC have been detected in patients with
mood disorders, and LC-CA1 hippocampal projections are decreased in mice models of chronic social
defeat stress (CSDS) and chronic footshock stress (CFS) [110,111]. Remarkably, an early degeneration
of NE-LC neurons occurs in AD [112], and such a phenomenon was recently linked to depressive
symptoms characterizing early AD stages [113]. In detail, a minimal loss of NE-LC neuronal population
following a bilateral infusion of the neurotoxin 6-OHDA produces depressive-like behaviors in mice,
which can be reversed by administration of NE precursors [113]. Thus, by stimulating NE and
NGF/BDNF synthesis, H. erinaceus may produce plastic effects which are expected to counteract
behavioural alterations besides neurotoxicity. In fact, H. erinaceus reverses early learning and memory
deficits which are induced by amyloid beta peptides independently of neuropathology in AD mice
models [114].
Eventually, R. rosea possesses remarkable multi-target activities on both cellular and systemic
levels of stress-response regulation [115]. As assessed through RNA microarray studies in neuroglial
cell lines, R. rosea modulates the transcription of various biological and molecular mediators that
are associated with emotional behavior, particularly aggressive behaviour [116]. In detail, R. rosea
regulates various components of the antioxidant, anti-inflammatory, neuroendocrine, neurotrophic and
neurotransmitter receptor pathways, which are likely associated with both its neuroprotective potential
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and beneficial effects on mood [15]. R. rosea increases the levels of both monoamines and acetylcholine
(Ach) in nerve terminals and is likely bound to its mental health-promoting effects concerning both
mood and cognition [91,115–121]. However, compared with S. baicalenis and H. erinaceus, R. rosea
produces more significant effects at the level of the 5-HT system, by increasing 5-HT and 5-HT1A
receptor levels [121,122]. R. rosea also produces remarkable anti-stress effects by modulating HPA axis
and opioid peptides release and by acting as a corticotrophin-releasing factor (CRF) antagonist, thus
blunting cortisol release [37,115,118]. Again, R. rosea inhibits stress-induced molecular events including
abnormal cortisone release, nitric oxide production and pJNK expression [123]. At the molecular
levels, R. rosea inhibits stress-induced over-activation of the pSAPK/pJNK pathway, which is bound to
oxidative stress as well as altered synaptic plasticity and glucocorticoid receptors (GR) responsivity,
and this is specifically implicated in its antidepressant-like effects [36,123]. At the same time, R. rosea
stimulates the release of stress-related molecules, namely neuropeptide Y (NPY) and Hsp72, which
likely represents a defense cellular response aimed at increasing tolerance and adaptation to stress [124].
These findings are in line with a growing body of both preclinical and clinical evidence indicating its
potential use in the prevention and treatment of stress- and age-related cognitive and mood alterations,
including fatigue, weakness, depression and anxiety [15,43,110,115,117,125–127].
3. S. baicalensis, H. erinaceus and R. rosea: Anxiolytic/Antidepressant Effects in Experimental and
Clinical Studies
3.1. S. baicalensis in Experimental Models
3.1.1. Anxiety
The anxiolytic-like effects of S. baicalensis have been demonstrated since the early 1990s [128].
Administration of S. baicalensis extract and baicalin was shown to normalize all of the hormonal
metabolic disturbances which develop in rats exposed to stress by fixation. These include alterations in
insulin, urea, glucose, corticotrophin and hydroxycorticosteroids levels, which are bound to alterations
of hypothalamic and adrenocortical functional activity [128].
Recently, baicalin emerged as an alternative, GABAA receptor benzodiazepine (BZ)-site ligand
possessing minimal side effects along with a selective activity profile compared with BZs [9,129–131].
Despite common prescription of conventional BZs as potent anxiolytics, the numerous side effects
they produce such as sedation, myorelaxation, amnesia, and addiction, have continuously prompted
the search for alternative BZ site ligands with less side effects. Baicalin was identified as a BZ-site
ligand since the early 2000s [129], and this was associated with anxiolytic-like activity occurring in the
absence of sedative and myorelaxant side effects, as assessed in mice through Vogel conflict test and
elevated plus maze test [130,131].
Subsequent studies also assessed the effects of baicalin on GABAA receptor binding selectivity as
well as on the cognitive impairment, anticonvulsant and motor incoordination side effects that are
associated with conventional anxiolytics [9]. Contrarily to diazepam (3 mg/kg), baicalin (3.3–30 mg/kg)
acts as a subtype-selective partial agonist of GABAA receptors, exhibiting no amnesic, anticonvulsant,
and motor incoordination activities in mice, as assessed through the step-through passive avoidance
test, picrotoxin-induced seizure test and rotarod test, respectively. Contrarily to the full agonist
diazepam, baicalin shows a selectivity profile by acting throughα2- andα3-containing GABAA receptor
subtypes [9]. Electrophysiological studies showed that baicalin mildly potentiates GABA-induced
currents, and this can be abolished by co-application of the BZ site antagonist flumazenil. Thus, baicalin
acts a partial BZ-site agonist, which may explain its anxiolytic activity with limited side effects.
The anxiolytic-like effects of centrally administered baicalein were also evaluated in mice [132].
Baicalein exerts an anxiolytic-like effect already at low doses (0.02, 0.2 pmol), increasing the time
spent in open arms and the head-dipping while reducing the stretched-attend postures in the elevated
plus-maze. These effects are abolished by pretreatment with dehydroepiandrosterone sulfate (DHEAS)
and pentylenetetrazol (PTZ) but not dl-p-chlorophenilalanine ethyl ester (PCPA) and flumazenil (FMZ),
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suggesting that the pharmacological activities of baicalein may dependent on GABAergic ligand sites
other than BZ ones [132].
3.1.2. Chronic Corticosterone-Induced Depression
In mice models of chronic corticosterone (CORT)-induced depression, baicalin (40, 80, and
160 mg/kg) administered either orally or intragastrically produces anxyolitic- and antidepressant-like
effects which are reproduced by the conventional antidepressant fluoxetine [133,134]. In fact, baicalin
rescues the behavioral alterations induced by chronic CORT, namely the decreased time spent in the
center and non-periphery zone in the open-field test, the increased immobility time in tail suspension
test and forced swimming test, as well as the decreased time spent in open arms in the elevated plus
maze test [133,134]. In chronic CORT-treated mice, baicalin restores the aberrant negative feedback
of HPA axis, as assessed by dexamethasone suppression test [133]. By applying proteomics and
systems biology, biological processes related to glucocorticoid receptor (GR) signaling were identified
as potential molecular targets. In fact, baicalin selectively targets CORT-induced alterations in the
nuclear/cytoplasmic GR distribution in the hippocampus. In detail, baicalin selectively reverses
the CORT-induced decrease of GR levels in cytoplasm and the concomitant increase of GR levels
in nucleus [133]. On the other hand, the CORT-induced enhancement of GR in nucleus, as well
as the increased GR phosphorylation status at its crucial serine residues are similarly decreased by
both baicalin and fluoxetine [133]. Baicalin, similar to fluoxetine, restores normal GR function by
normalizing the levels of two GR-phosphorylating proteins, namely FK506-binding protein 51 (FKBP5)
and serum- and glucocorticoid-inducible kinase 1 (SGK1) [134]. The antidepressant-like effects of
baicalin are also associated with neurogenic activity. In fact, baicalin reverses the CORT-induced
decrease in Ki67- and doublecortin (DCX)-positive cells in the dentate gyrus of the hippocampus [134].
3.1.3. Olfactory Bulbectomy-Induced Depression
In olfactory bulbectomy (OBX) mice models of depression, baicalin treatment (20 and 40 mg/kg)
significantly reverses the abnormal levels of serum corticosterone, while normalizing behavioural
alterations assessed through sucrose consumption, open field test, and forced swimming test [135].
This is associated with downregulation of the inflammatory factors IL-1β, IL-6, and TNF-α in the
hippocampus and hypothalamus, which occurs through inhibition of the SIRT1-NF-kB pathway [135].
The antidepressant-like effects of baicalin (20 and 40 mg/kg) in OBX rat models are also associated with
anti-oxidant and antiapoptotic activity. In fact, baicalin reverses OBX-induced alterations in the levels
or activity of MDA and GSH-Px while preventing apoptotic protease-activating factor-1 (APAF-1)
expression and subsequent caspase-mediated signalling cascades [136].
In the context of olfactory dysfunction-related depression, the effects of baicalin were evaluated in a
transgenic mice model featuring hyperactivation of APPL2 (adaptor protein phosphotyrosine interacting
with PH domain and leucine zipper 2). This mutation leads to depressive-like behaviour due to abnormal
GR activity, impaired neurogenesis at olfactory system and loss of olfactory sensitivity [137]. Baicalin
treatment blunts APPL2/GR signaling pathway and it improves neurogenesis at the subventrivular zone,
olfactory bulb, and hippocampus in APPL2-Tg mice and also in a chronic CORT model. Behavioral
tests revealed that baicalin similarly attenuates depressive- and anxiety-like behavior while improving
olfactory functions both in APPL2-Tg mice and the chronic CORT depression model [137].
3.1.4. Streptozotocin-Induced Depression
S. baicalensis bioactive compounds produce antidepressant-like and cognitive-enhancing effects
by targeting systemic metabolic alterations which are commonly associated with neurological and
mental disorders [8]. In detail, in rat models of diabetes mellitus established via intraperitoneal
injection of streptozotocin, baicalin (50, 100 and 200 mg/kg) administered daily for 7 weeks reverses
depressive-like and cognitive alterations such as decreased percentage of time spent in the target
quadrant, the number of times of crossing the platform in the water maze test, as well as the
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increase in escape latency and mean path length in the water maze test [8]. At the molecular level,
baicalin counteracts streptozotocin-induced neuronal cell loss as well as the decline and increase of
hippocampal acetylcholine transporter (ChAT) and acetylcholinesterase (AChE) levels, respectively.
This is accompanied by increased levels of pERK, Bcl 2, and BDNF. At the same time, baicalin decreases
plasma glucose levels and counteracts apoptosis by reversing the increase in phosphorylated c-Jun
N-terminal kinase (pJNK), p38, caspase 3 and Bax levels [8].
3.1.5. Chronic (unrestraint) Mild Stress-Induced Depression
In mice models of chronic (unrestraint) mild stress (CUMS), baicalin (25, 50 and 60 mg/kg)
alleviates depression-like behavior by increasing sucrose consumption and reducing immobility
times in the tail suspension and forced swim tests [138–140]. These effects are associated
with a reduction of inflammatory cytokines IL-1β, IL-6, and TNF-α levels in serum and in
the hippocampus [138,139]. In mice subjected to CUMS baicalin also abrogates the increase in
NMDAR/NR2B and Ca2+/calmodulin-dependent protein kinase II (CaMPK-II) as well as the decrease
in pERK, while counteracting reactive oxygen species (ROS) production [138]. Baicalin administration
also counteracts CUMS- and neuroinflammation (LPS)-induced depressive-like behavior in mice,
and this occurs through downregulation of TLR4 via the HMBG1/NF-kb [139] and PI3K/AKT/FoxO1
pathways [140].
Baicalin administration exerts antidepressant-like and neuroprotective effects by counteracting
oxidative stress and apoptosis in CUMS models [141]. In fact, it reduces the level of MDA, caspase-1
and IL-1β while increasing SOD in the hippocampus. These effects are mediated by inhibition of
glycogen synthase kinase-3 (GSK3β)/ NF-κB / NLRP3 (Nucleotide-binding domain, leucine-rich repeat,
pyrin domain containing protein 3) signaling pathway [141]. This is in line with a reduction of NLRP3
inflammasome levels which is detected in the prefrontal cortex of CUMS mice following administration
of baicalin (20, 40mg/kg) [142].
Chronic CMS models of depression have been also employed to compare the effects of baicalin
with fluoxetine [35,143]. Mice from both the baicalin and fluoxetine groups show a decrease in
depression-like behavior compared with controls. Both baicalin (25, 50, 100 mg/kg) and fluoxetine
(10 mg/kg) induce plastic changes by counteracting the CMS-induced decrease in the expression levels
of the synaptic proteins synaptophysin (SYP), postsynaptic density protein-95 (PSD95), as well as TrkB,
Rac1, cofilin and BDNF [143]. Remarkably, baicalin treatment alleviates the ultrastructural alterations
occurring in the hippocampal CA3 area of the CMS group [143].
In another study on the CMS rat model, the effect of orally administered baicalin at the dose of
25 mg was as potent as that of fluoxetine 20 mg/kg [35]. This is associated with inhibition of monoamine
oxidase A and B (MAO A/B) activity by baicalin [35]. In line with the beneficial effects of baicalin
in counteracting monoamine-related alterations, these results suggest that baicalin may produce an
antidepressant-like effect in vivo, at least in part, through MAO inhibition [35]. In CMS models,
the antidepressant-like effects of chronic baicalin treatment (10, 20, 40 mg/kg) are also associated
with anti-inflammatory activity, consisting of a reduction in the mRNA expression and activity of
cyclooxygenase-2 (COX-2), as well as prostaglandin E(2) (PGE(2)) levels in the frontal cortex and
hippocampus [144].
In CUMS mice, baicalin administration, through activation of the Akt/FOXG1 pathway, also
promotes neurogenesis by increasing the number of DCX-positive cells, while fostering neuronal
maturation, differentiation and survival [145]. These findings are reproduced in CUMS mice which
are administered with full Radix Scuellariae extract (500, 1000 mg/kg) [146], which markedly reverses
the shortened escape latency in morris maze test, the reduced immobility time in tail suspension test
and in forced swimming test, as well as the increased sucrose consumption in sucrose preference test.
These effects are associated with an enhancement of cAMP/PKA-dependent neurogenesis, as shown by
the reversal of CUMS-induced reduction in BrdU, DCX and NeuN in the mice hippocampi [146].
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Overall, these findings suggest that the antidepressant-like effects of baicalin are due to inhibition
neuroinflammation and oxidative stress, potentiation of neurogenesis and neuronal differentiation, as
well as amelioration of alterations associated with HPA axis hyperactivity, GABA and DA systems
(Figure 2). Encouraging results are also achieved using S. baicalensis radix extract [146], though further
experimental studies are needed to confirm its antidepressant-like action compared with baicalin alone.
3.2. S. baicalensis in clinical studies
To date, clinical studies assessing specifically the antidepressant effects of S. baicalensis are still
lacking. In the literature, there are only two available studies reporting the tolerability and the cognitive
enhancing properties of S. baicalensis in humans. In detail, Pang et al. investigated the pharmacokinetics,
safety and tolerability of baicalein after a multiple-ascending-dose protocol in thirty-three healthy
Chinese volunteers. Participants were randomized to receive baicalein chewable tablets (n = 8 per
dose regimen) or placebo (n = 2 per dose regimen). Dosing regimens were 200, 400, and 800 mg once
daily on days 1 and 10, and twice daily on days 3–9. In the dose range of 200–800 mg, multiple-dose
oral baicalein administration was safe and well tolerated [57].
In a human clinical trial, subjects who were orally given 300 mg of S. baicalensis extract (formulation
UP326) for 30 days showed a marked improvement in speed and accuracy of processing complex
information in computer tasks [58]. They also showed a reduced standard deviation of performance
compared to baseline and the placebo group. All study compounds were well tolerated with no reports
of serious or unexpected adverse effects. Thus, S. baicalensis may help to maintain memory, sustain
speed of processing, and reduce the number or ageing-associated memory decline. Nonetheless, it
cannot be argued that S. baicalensis has antidepressant effects in humans. This is also based on a much
higher concentration of baicalin used in experimental compared with clinical studies.
3.3. H. erinaceus in Experimental Studies
Recent preclinical and clinical studies have shown that besides enhancing cognitive function and conferring
neuroprotection, H. erinaceus also improves depression, anxiety, and sleep disturbances [39,115,147,148]. In line
with this, recent studies have also been exploring the feasibility of mushrooms as potential fortified
foods enriched with lithium, a well-known and gold standard mood stabilizer [4]. Co-cultivation
of H. erinaceus with 0.25–1.0 mM lithium chloride results in a concentration-dependent uptake
of lithium and its accumulation in H. erinaceus fruiting bodies. Such a supplementation does
neither alter mushroom biomass, appearance, shape or size nor does it produce significant effects on
mineral composition. As calculated, consumption of 100 g dry weight of H. erinaceus fruiting bodies
supplemented with 1.0 mM lithium would constitute 69% of the provisional recommended dietary
daily intake of lithium (1.0 mg). This suggests that H. erinaceus deserves to be further studied in
experimental models and eventually, human studies in terms of both safety and potential synergistic
activity with other herbs or conventional mood stabilizers [4].
Compared with saline-treated mice, dietary administration of H. erinaceus ethanolic fruit body
extracts at 60 mg/kg once a day for 4 weeks reduces anxiety and depressive-like behaviour as assessed
through elevated plus-maze, tail-suspension and forced swimming tests [149]. This is associated with
increased proliferation of hippocampal progenitors and enhanced neurogenesis, which was evaluated
by immunohistochemistry of proliferating cell nuclear antigen (PCNA) and Ki67 in the subgranular
zone of the hippocampus, and BrdU/NeuN-positive cells in the dentate gyrus [149]. However, the
present study carries an inherent limitation since healthy mice instead of depression mice models were
employed as positive controls [149].
3.3.1. Inflammation-Related Depression
The effects of H. erinaceus were evaluated in a mouse model of inflammation-induced depression
consisting of intraperitoneal LPS administration [13]. Oral administration of the H. erinaceus
fruit body extract amycenone (200 mg/kg) prior to a single administration of LPS (0.5 mg/kg)
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improves depressive-like behaviour compared with LPS-treated mice, as shown by a reduction
in the immobility time measured at tail-suspension test and forced swimming tests. At the molecular
level, H. erinaceus reduces serum levels of the pro-inflammatory marker TNF-α while increasing the
anti-inflammatory cytokine interleukin-10 (IL-10). These effects are reproduced by the administration
of paroxetine (30 mg/kg) suggesting that H. erinaceus extracts may be beneficial in inflammation-related
depression [13].
3.3.2. Restraint Stress-Induced Depression
The findings on the anti-inflammatory and neurotrophic properties of H. erinaceus in relation with
its antidepressant-like efficacy were recently reproduced in a mice model of repeated restraint stress
(RS) [14]. Mice were orally administered H. erinaceus mycelium ethanolic extract at the daily dose of 100,
200 or 400 mg/kg b.w. for 4 weeks, and RS protocol was started at 2 weeks of H. erinaceus administration.
Compared with saline-treated animals subject to RS, H. erinaceus, especially at the highest doses, could
reverse the depressive-like behaviour caused by RS, namely the increased immobility time in the tail
suspension and forced swimming tests, as well as the increased number of entries and the time spent
in the open arm. This was accompanied by an increase in monoamine neurotransmitters levels along
with a reduction of the pro-inflammatory factors IL-6, TNF-α and NF-κB, and the upregulation of
BDNF [14]. The molecular mechanisms of action of H. erinaceus are summarized in Figure 4.
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effects. H. erinaceus and its bioactive ingredients (mostly erinacines) potentiat monoamine, and mostly
norepinephrin (NE) synthesis and r lease. At the same time, they promote TrkB-r lated increase
in pERK and pAKT and the subsequent synthesis of neurotrophic factors (BDNF and NGF) along
with neurogenesis. H. erinaceus promotes anti-inflammatory effects through inhibition of TLR4/NF-kb,
PI3K/AKT/Nf-κB axes. H. erinaceus also protects from apoptosis, mitochondrial damage and promotes
anti-oxidant effects.
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3.4. H. erinaceus in Clinical Studies
In thirty females suffering from depression, menopause, sleep disturbances and indefinite
complaints, the effects of H. erinaceus intake were evaluated by using the Kupperman Menopausal
Index (KMI), the Center for Epidemiologic Studies Depression Scale (CES-D), the Pittsburgh Sleep
Quality Index (PSQI), and the Indefinite Complaints Index (ICI) [150]. H. erinaceus cookies containing
0.5 g of fruit bodies powder or placebo cookies containing no powder were taken for 4 weeks. Following
H. erinaceus treatment, each of the CES-D and the ICI score was significantly lower than that before
treatment. Moreover, compared with placebo, H. erinaceus-receiving group showed significantly
lower scores associated with insensitivity, agitation, irritation, palpitation and anxiety, suggesting that
H. erinaceus may hold potential in reducing depression and anxiety [93]. However, no differences were
observed between the two groups in the menopause and sleep-quality indexes.
A recent study carried out on 77 volunteers affected by overweight or obesity reported that a
daily, 8-week oral supplementation with H. erinaceus (80% mycelium extract and 20% fruiting body
extract), coupled with a low calorie diet regimen improves depression, anxiety, sleep, and binge
eating compared with subjects undergoing low calorie diet only [91]. This is correlated with increased
circulating pro-BDNF levels and pro-BDNF/BDNF ratio, despite the lack of any significant changes in
BDNF circulating levels.
In an 86-year-old male patient with recurrent depressive disorder and mild cognitive impairment
which developed during antidepressant therapy, Mirtazapine treatment was combined with H. erinaceus
extract (formulation Amyloban®3399) [151]. At 6 months of H. erinaceus daily intake, the patient was
free of depression and he showed improved cognitive function and body weight in the absence of
adverse reactions, suggesting that H. erinaceus could be a useful antidepressant, especially in geriatric
depression [151].
H. erinaceus extract (Amyloban®3399) intake for 4 weeks was also shown to counteract sleep
disturbances in a pilot study on female undergraduate students [152]. This was assessed through
subjective sleep-quality and well-being questionnaires GHQ-28 and PSQI (Pittsburg Sleep Quality
Index) and also through the levels of salivary free- 3-methoxy-4-hydroxyphenylglycol, an index of
chronic stress and depressive symptoms reflecting sympathetic nervous system activity. The latter was
found to be increased after awakening, strengthening the evidence for an improvement in anxiety and
sleep quality following H. erinaceus intake [152].
3.5. R. rosea in Experimental Studies
3.5.1. Behavioral Despair-Related Depression
The anti-depressant-like activities of R. rosea root’s extract have been assessed in a behavioral
despair rat model of depression consisting of repeatedly forced swimming in a restricted space [36].
This leads to immobility reflecting a state of despair that is effectively reversed by antidepressant
compounds in humans. Thus, the effects of R. rosea extracts were compared with the standard
anti-depressant imipramine and with the naturally-occurring H. perforatum extract [36]. The herbal
compounds were administered three times, once immediately after the initial exposure to the forced
swimming assay, as well as 24 and 1 h prior to re-exposure. Single doses of standard anti-depressants
were administered 30 min prior to stress re-exposure. R. rosea root extract (10, 20 and 50 mg/kg)
administered either orally or intravenously increases the swimming time of rats in a dose dependent
manner, and remarkably, its anti-depressant-like effects are greater compared with those produced
by imipramine and H. perforatum. The behavior despair assay was also applied to study the effects
of five single bioactive compounds isolated from R. rosea roots, each one administered at the dose of
0.26 mg/kg (namely rhodioloside/saliroside, tyrosol, rosavin, rosarin and rosin). Rhodioloside/saliroside
exhibits higher anti-depressant effect compared with other compounds; however, the strongest effect
is produced by the fixed combination of the five compounds, indicating a synergistic mechanism of
action of R. rosea bioactive ingredients [36,99].
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3.5.2. Olfactory Bulbectomy-Induced Depression
Saliroside oral administration (20, 40 mg/kg) for 2 weeks also alleviates OBX-induced
depressive-like behavior in rats, as assessed through sucrose consumption, open field test, forced
swimming test and tail suspension test [19,20]. This is associated with reduced TNF-α, IL-1β, IL-6
and NF-κB levels in the hippocampus and prefrontal cortex along with a concomitant increase in
BDNF expression in the hippocampus [19,20]. Besides, similarly to the antidepressant amitriptyline
(10 mg/kg), saliroside markedly restores the depletion of 5-HT and NE levels in the prefrontal cortex
of OBX rats [20]. Saliroside also attenuates CRF expression in hypothalamus while reducing serum
corticosterone levels [19].
3.5.3. Inflammation-Related Depression
In a mice model of LPS-induced depression, a five-day pre-treatment with saliroside (12 and
24 mg/kg), similar to fluoxetine (20 mg/kg) produces antidepressant-like behavior through
anti-inflammatory, monoamine-enhancing and neurotrophic effects [153]. In detail, saliroside reduces
IL-6 and TNF-α levels in the serum and NF-κB levels in the mice hippocampi. At the same time,
saliroside upregulates TrkB/BDNF levels and restores 5-HT and NE levels in the prefrontal cortex of
LPS-depressed mice compared with the vehicle group [153]. A recent study also evaluated the effects
of both single and combined oral administration of R. rosea (250, 500 mg/kg) and Curcuma longa (250,
500 mg/kg) extracts in a CMS mice model of depression followed by LPS-induced inflammation [154].
The combination of R. rosea 500 mg/kg and Curcuma 500 mg/kg remarkably reverses depression-like
behavioral changes while providing synergistic anti-inflammatory effects, namely reduced levels of
TNF-α and IL-6 in CMS exposed and LPS-challenged mice [154].
3.5.4. Chronic Mild Stress-Induced Depression
The antidepressant-like effects of R. rosea (1.5 g/kg/day for three weeks) in CMS rat models are
also bound to stimulation of neuronal stem cells proliferation [155]. In detail, R. rosea improves
depressive-like behavior while increasing the amount of healthy, PCNA-positive cells and preventing
the occurrence of damaged, Caspase 3-positive neuronal cells [155].
In female CMS rat models, daily R. rosea administration (10, 15 and 20 mg/kg) for three weeks
produces antidepressant-like behaviors which are comparable with those induced by fluoxetine
(10 mg/kg). In detail, R. rosea reverses the CMS-induced decrease in sucrose intake, moving behaviour,
minimized weight gain and dysregulation of their oestrous cycle [118].
In rat models of CMS-induced depression, R. rosea extract (1.5, 3 and 6 g/kg) administration for
3 weeks fully recovers 5-HT hippocampal levels already at the lowest dose. This is accompanied by
potentiation of neural stem cell proliferation as assessed through BrdU immunohistochemistry [121].
Thus, serotonin may be crucially involved in the beneficial effects of R. rosea on mood disorders.
These findings are reproduced in mice models showing depressive-like behavior following nicotine
withdrawal [122]. In detail, in rats previously treated for 14 days with nicotine (2 mg/kg) and the
selective 5-HT1A receptor antagonist WAY 100635 (1 mg/kg), R. rosea (5, 10, 20, and 40 mg/kg) oral
administration prevents depressive-like behaviors related with nicotine withdrawal, as assessed
through the abstinence scale, the immobility time on forced swimming test and marble burying test.
These effects are associated with an increase in the diencephalic content of 5-HT and the expression of
5-HT1A receptor [122].
3.5.5. Prepulse Inhibition-Related Depression and Psychosis
R. rosea effects were recently evaluated in murine models of prepulse inhibition, an established
operational measure of sensorimotor gating which is impaired in a variety of mental disorders featuring
psychosis [156]. In detail, R. rosea extract robustly reverses prepulse inhibition deficits which are
induced by either the dopamine D2 receptor agonist apomorphine or the NMDA receptor antagonist
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dizocilpine. Thus, R. rosea may possess antipsychotic effects, though the underlying molecular
mechanisms remain to be elucidated [156].
In summary, the antidepressant mechanisms of R. rosea and saliroside might be associated with
antioxidant and anti-inflammatory effects and the regulation of monoamine and cholinergic systems
and HPA axis activity (Figure 5).
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anxiolytic/antidepressant-like effects. By acting as MAO A/B inhibitor, R. rosea and its main bioactive
ingredient (saliroside) induce monoamine, and mostly 5-HT release while potentiating 5-HT synthesis
and the expression of 5-HT1A receptors. R. rosea also potentiates Ach release while acting as an Ach
esterase (AchE) inhibitor. At the same time, R. rosea acts as a JAK/STAT and SAPK/JNK pathway inhibitor
to promote the synthesis of neurotrophic factors along with anti-inflammatory and antioxidant effects.
JAK/STAT and SAPK/JNK pathway inhibition is also associated with R. rosea-induced downregulation of
CRF receptors and inhibition of GR phosphorylation at crucial serine residues related to HPA axis activity.
3.6. R. rosea in Clinical Studies
In humans, R. rosea modulates cortical plasticity by preventing the activity-dependent reduction
in neuronal synaptic efficacy [157]. A transcranial Direct Current Stimulat on (DST) study evaluated
the effect of a single R. rose extract dose on the plas ic effects induced by anodal and cathodal
transcranial stimulation in twenty-eight healthy volunteers receiving 500 mg of either R. rosea or
placebo. Acute R. rosea intake prevents cathodal DST-induced LTD-like plasticity, despite not affecting
cortical excitability [157]. Thus, the adaptogenic, mental health-promoting effects of R. rosea are likely
bound to plastic mechanisms of action in the brain.
3.6.1. Anti-Fatigue and Anti-Stress Effects
The antiasthenic effects of R. rosea were evaluated by a randomized double-blind cross-over trial
on a group of 56 young, healthy physicians during night duty [158]. The effects were measured as
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total mental performance calculated as Fatigue Index and through different perceptive and cognitive
tests which were performed before and after night duty. In the R. rosea treatment group, significant
improvements were observed in all the tests during the first two weeks’ period, and no side-effects
were reported [158].
The effects of a standardized R. rosea extract (SHR-5, 50 mg) were also assessed in foreign students
during a stressful examination period of 20 days [159]. The study was performed as a double-blind,
randomized and placebo-controlled trial with low repeated dose regime. The physical and mental
performance, which was assessed before and after the period, was based on objective as well as on
subjective evaluation. Compared with placebo, significant improvements were observed in the R. rosea
group as it concerns physical fitness and mental fatigue. The self-assessment of the general well-being
was also significantly improved in the R. rosea group [159]. Despite these encouraging results of R. rosea
intake, its dosage appeared suboptimal in improving mental work performance evaluated through the
correction of text tests or neuro-muscular tapping test [159].
This issue was addressed by a subsequent clinical study which was carried out to assess the
differences between the effects of two R. rosea doses on mental work capacity during periods of fatigue
and stress [160]. This consisted of a randomized, double-blind, placebo-controlled, parallel-group
clinical study on 161 cadets who were randomized into four groups, namely R. rosea (2x185.0 mg)-,
R. rosea (3x185.0 mg)-, placebo-receiving and non-treatment group. The results showed a pronounced
antifatigue effect along with improved work performance for both R. rosea dosages compared with the
placebo group. No significant differences were observed between the two dosage groups. However,
there was a slight trend in favour of the lower dose in the psychometric tests, which was not observed
in the physiological tests [160]. Thus, R. rosea can effectively reduce general fatigue and anxiety under
stressful conditions.
3.6.2. Anxiolytic and Antidepressant Effects
A pilot study on ten adults with a diagnosis of generalized anxiety disorder (GAD) was conducted
to specifically evaluate the anxiolytic efficacy of R. rosea [161]. Subjects receiving a daily dose of 340 mg
of R. rosea extract for 10 weeks show significant decreases in mean Hamilton Anxiety Rating Scale
(HARS) scores at endpoint, witnessing for significant improvement in GAD symptoms. Adverse events
were generally mild or moderate in severity, the most common being dizziness and dry mouth [161].
Clinical trials of the late 1980s demonstrated that, when administered together with tricyclic
anti-depressants, R. rosea leads to a marked reduction in the side effects of the drugs, while producing
additional beneficial effects on depressive symptoms [162,163].
More recently, the antidepressant effects of R. rosea extract were confirmed by a phase III clinical
trial which was carried out as a randomized double-blind placebo-controlled study over a period of six
weeks [69]. Participants fulfilling diagnostic criteria of mild-to-moderate depression were randomized
into three groups: the first (31 patients) receiving two tablets daily of R. rosea (SHR-5, 340 mg/day);
the second (29 patients) receiving two R. rosea tablets twice per day (SHR-5 680 mg/day), and the
third (29 patients) receiving two placebo tablets daily. The efficacy of SHR-5 extract with respect to
depressive complaints was assessed on days 0 and 42 of the study period through Beck Depression
Inventory (BDI) and Hamilton Rating Scale for Depression (HAMD) scores. In the groups receiving
either 340 or 680 mg/day R. rosea, there was a significant overall improvement in depression, together
with insomnia, emotional instability and somatization. No serious side-effects were reported in any of
the groups, concluding that R. rosea exhibits anti-depressive efficacy in patients with mild to moderate
depression [69].
A subsequent, randomized double-blind, 12-week, proof-of-concept trial reproduced safety and
efficacy data on the antidepressant action of R. rosea compared with the conventional antidepressant
sertraline in adult outpatients with mild to moderate depression [164,165]. Patients were randomized
in three groups receiving capsules of either R. rosea powdered extract (SHR-5, 340 mg), sertraline
(50 mg) or placebo (i.e., lactose monohydrate). The outcomes were evaluated through HRSD, BDI
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and Clinical Global Impression (CGI) scores. For the first two weeks all patients received one capsule
daily. Subjects showing ≤ 50% reduction in HRSD score compared to baseline had the dose increased
to 2 capsules daily during the following two weeks of therapy. This procedure was continued every
2 weeks for subjects with ≤ 50% reduction in HRSD score compared to baseline, up to a dose of
4 capsules daily for the last six weeks of therapy. Outcome measurements were obtained at baseline
and after 2, 4, 6, 8 and 12 weeks of treatment. No statistically significant differences were observed
over time for HRSD, BDI or CGI scores among treatment groups. A slightly greater decline in HRSD
scores by week 12 was observed for sertraline compared with R. rosea and placebo. Nonetheless,
clinically meaningful odds ratios of global improvement emerged by week 12 for R. rosea and sertraline
compared with placebo; in detail, compared with placebo the odds of improvement were 1.4 and
1.9 times for R. rosea and sertraline, respectively. Remarkably, more subjects reported study-related
adverse for sertraline (63.2%) compared with R. rosea (30.0%) and placebo (16.7%). While two subjects
prematurely discontinued sertraline treatment, no subject prematurely discontinued R. rosea or placebo.
In summary, R. rosea possesses milder antidepressant efficacy, yet, higher tolerability compared with
conventional antidepressants [164,165].
The impact of an R. rosea extract (200 mg Vitano®) on self-reported anxiety, stress, cognition,
and other mood symptoms was evaluated by a non-placebo controlled trial on eighty mildly anxious
participants who were randomized into two groups, one receiving R. rosea twice a day and one receiving
no treatments [166]. Self-report measures and cognitive tests were completed at four testing sessions
over a period of 14 days. The R. rosea-receiving group self-reported a significant reduction in anxiety,
stress, anger, confusion and depression at 14 days and a significant improvement in total mood, though
no relevant differences in cognitive performance between the groups were observed. Moreover, R. rosea
presented a favourable safety/tolerability profile [166].
In a recent preliminary observational study, forty-five adults suffering from mild or moderate
depression were supplemented with a combination of R. rosea and saffron extracts (one tablet, 154 mg
of R. rosea and 15 mg of saffron) twice a day for 6 weeks [167]. After 6 weeks (D42) of supplementation,
the HARS scores decreased by 58% in nearly 85% of patients. A significant drop in both Hospital
Anxiety and Depression Scale anxiety and depression scores was also observed at D42, the decrease
being significant from 2 weeks of supplementation. At the end of the study, both general practitioners
and patients noticed significant improvements in depression symptoms. Safety was excellent, and
no serious adverse effects were recorded, suggesting that combination of R. rosea with other herbal
compounds deserves further investigation as a potential strategy for the management of mild-moderate
depression [167].
3.6.3. Obstructive Sleep Apnea- and Menopause-Related Mood Alterations
In patients with obstructive sleep apnea (OSA), R. rosea was shown to relieve anxiety and depressive
symptoms by inhibiting oxygen free radicals and lipid peroxidation [168]. This was assessed in ninety
patients with moderate and severe OSA presenting with negative emotions diagnosed by self-rating
depression scale (SDS) and self-rating anxiety scale (SAS). Compared with untreated controls, R. rosea
intake for 3 months significantly improved SDS and SAS scores, which is associated with an increase
in serum levels of SOD and a concomitant reduction of serum MDA levels [168].
As recently reviewed, R. rosea may also act as a potential selective estrogen receptor modulator
(SERM) in the prevention and treatment of menopause-related mood disturbances, including fatigue,
depression, as well as cognitive decline and memory impairment, cardiovascular disease, and
osteoporosis [169]. The mechanisms of action through which R. rosea ameliorates menopause-related
alterations include activation of intra-cellular signal transduction pathways downstream of estrogen
receptors, potentiation of antioxidant defence and anti-inflammatory effects through counteracting
NF-Kβ and TNF-α production [169].
A summary of both experimental and clinical studies on the antidepressant effects of S. baicalensis,
H. erinaceus and R. rosea is provided in Table 1.
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Table 1. Experimental and clinical studies centered on the antidepressant-like mechanisms and potential of S. baicalensis, H. erinaceus and R. rosea.
Experimental Models of Depression S. baicalensis H. erinaceus R. rosea
Chronic corticosterone-induced
depression
(CORT)
Baicalin (40, 80, and 160 mg/kg) [133,134]
↑cytoplasmic GR levels ↓nuclear GR levels
↓GR phosphorylation
↑negative feedback of HPA axis [133]
↑neurogenesis (Ki67- DCX-positive cells) in the
dentate gyrus of the hippocampus [134].
Olfactory bulbectomy-induced
depression
(OBX)
Baicalin (20 and 40 mg/kg) [135–137]
↓serum corticosterone [135]
↓IL-1β, IL-6, and TNF-α in the brain via inhibition
of the SIRT1-NF-kB [135]
↓oxidative stress and apoptosis [136]
↑GSH-Px and
↓MDA, APAF-1 and caspases
↑neurogenesis and olfactory function via APPL2/GR
signaling pathway [137].
Saliroside (20 and 40 mg/kg) [19,20]
↓TNF-α, IL-1β, IL-6 and NF-κB in the
hippocampus and prefrontal cortex
↑BDNF expression in the hippocampus
[19,20]
↑5-HT and NE levels in the prefrontal cortex
[20]
↓CRF expression in hypothalamus and
↓serum corticosterone levels [19].
Chronic (unrestraint) mild
stress-induced depression
(CUMS)
and
Chronic mild stress + inflammation
(CUMS+LPS)
Baicalin (10, 20, 25, 40, 50, 60, and 100 mg/kg)
[35,138–145]
↓monoamine oxidase A and B (MAO A/B) activity
[35]
↓IL-1β, IL-6, and TNF-α in serum and in the
hippocampus [138,139]
↓COX-2 and PGE(2) in the brain [144]
↓TLR4 via the HMBG1/NF-kb and PI3K/AKT/FoxO1
pathways [139,140].
↑SOD and ↓ROS, MDA and caspase 1 [138,141]
via ↓NMDAR/NR2B, ↓Ca2+/CaMPK-II
and ↑pERK [139],
and
↓GSK3β/ NF-κB / NLRP3 [141,142]
↓ultrastructural hippocampal alterations
↑synaptic proteins SYP PSD95, TrkB, Rac1, cofilin
↑BDNF [143]
↑neurogenesis (DCX-positive cells) ↑neuronal
maturation, differentiation and survival [145].
Radix Scuellariae extract (500 and 1000 mg/kg) [146]
↑cAMP/PKA-dependent neurogenesis, ↑BrdU, DCX
and NeuN in the mice hippocampi [146].
R. rosea extract (1.5 g/kg/day) [155]
↑neuronal stem cell proliferation
↑PCNA-positive cells [155]
↓Caspase 3-positive neuronal cells [155].
R. rosea extract (1.5, 3 and 6 g/kg) [121]
↑5-HT hippocampal levels already at the
lowest dose.
↑neural stem cell proliferation
↑BrdU-positive cells [121].
R. rosea extract (250 and 500 mg/kg) [154]
↓TNF-α and IL-6 in CMS exposed and
LPS-challenged mice [154]
Potentiated effects when administered with
curcuma longa (500 mg/kg) [154].
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Table 1. Cont.
Experimental Models of Depression S. baicalensis H. erinaceus R. rosea
Streptozotocin (diabetes)-induced
depression
Baicalin (50, 100 and 200 mg/kg) [8]
↑hippocampal acetylcholine transporter (ChAT)
↓acetylcholinesterase (AChE)
↑pERK) ↑Bcl 2 ↑BDNF
↓pJNK) ↓p-p38, ↓caspase 3 and ↓Bax [8].
Inflammation (LPS)-induced depression
Baicalin (25, 50 and 60 mg/kg) [139,140]
↓TLR4 via the HMBG1/NF-kb and PI3K/AKT/FoxO1
pathways [139,140].
H. erinaceus fruit body extract amycenone
(200mg/kg) [13]
↓serum TNF-α
↑IL-10 [13].
Saliroside (12 and 24 mg/kg) [153]
↓serum IL-6 and TNF-α
↓NF-κB in the brain
↑TrkB/BDNF levels
↑5-HT and NE levels in the prefrontal cortex
[153].
Restraint stress-induced depression
H. erinaceus mycelium ethanolic extract (100,
200 and 400 mg7kg) [14]
↑monoamines levels
↓IL-6, TNF-α and NF-κB
↑BDNF [14].
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Table 1. Cont.
Clinical studies S. baicalensis H. erinaceus R.rosea
Baicalein chewable tablets
(200, 400, and 800 mg once daily on days 1 and 10,
and twice daily on days 3–9).
Safe and well tolerated. Related mood effects were
not analysed/reported [57].
S. baicalensis extract (300 mg daily for 30 days).
Safe and well tolerated.
Marked improvement in speed and accuracy of
processing complex information in computer tasks
[58].
H. erinaceus cookies
(0.5 g of fruit bodies powder for 4 weeks).
Lower scores associated with insensitivity,
agitation, irritation, palpitation and anxiety in
H. erinaceus-receiving women compared with
placebo group [155].
H. erinaceus (1.650 g/day, 80% mycelium extract
and 20% fruiting body extract for 8 weeks).
Safe and well tolerated. Coupled with a low
calorie diet improves depression, anxiety,
sleep, and binge eating compared with
subjects undergoing low calorie diet only [91].
Increases circulating pro-BDNF levels and
pro-BDNF/BDNF ratio [91].
H. erinaceus extract (Amyloban®) daily for 6
months combined with Mirtazapine.
Combats depression, and improves cognitive
function and body weight in the absence of
adverse reactions [151].
H. erinaceus extract (Amyloban®3399) intake
for 4 weeks counteracts sleep disturbances in a
pilot study on female undergraduate students.
It increases the levels of salivary free-
3-methoxy-4-hydroxyphenylglycol, an index
of chronic stress and depressive symptoms
reflecting sympathetic nervous system activity
[152].
R. rosea extract (340 mg/day for 10 weeks).
Improvement of general anxiety disorder
symptoms evaluated by HARS scores.
Generally mild adverse effects, the most
common being dizziness and dry mouth
[161].
R. rosea extract (SHR-5, 340 or 680 mg/day for
six weeks).
Safe and well tolerated. Improvement of
depressive symptoms, insomnia, emotional
instability and somatization compared with
placebo group [69].
R. rosea powdered extract (SHR-5 capsule,
340 mg, one capsule/day for the first week,
two capsules/day for the following two
weeks, up to up to 4 capsules/day for the last
six weeks).
Improves depressive symptoms compared
with placebo and produces antidepressant
effects which are comparable with sertraline
(50 mg). Fewer adverse effects were reported
for R. rosea compared with sertraline
[164,165].
R. rosea extract (Vitano®, 200 mg twice a day
for 14 days).
Safe and well tolerated.
Reduces self-reported anxiety, stress, anger,
confusion and depression, and overall
improvement in mood [166]
R. rosea extract (one tablet, 154mg, combined
with saffron tablet 15 mg, twice a day for 6
weeks).
Excellent safety, no serious adverse effects.
Improvements in HARS scores and
depression symptoms reported by both
general practitioners and patients [167].
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4. Conclusions and Future Perspectives
The evidence here reviewed suggests that S. baicalensis, H. erinaceus and R. rosea deserve to be
further investigated for their antidepressant/anxiolytic potential since they promote mental-health with
a wide margin of safety. As common neuroprotective and antidepressant-like effects, these compounds
promote synaptic plasticity and neurogenesis while counteracting oxidative stress, mitochondrial
alterations, and neuro-inflammation. These three herbs also improve cognitive functions by rescuing
Ach neurotransmission. These considerations are key in the light of the close association that exists
among depression, cognitive alterations and neurodegeneration, being the latter often accompanied or
even preceded by mood alterations [170,171]. In view of their antioxidant and mitochondrial protecting
effects, these herbs could be considered as an adjunct to standard antidepressant drugs which possess
side effects related to mitochondrial toxicity [172].
Despite common properties, each herb also produces specific, and potentially complementary
effects, mostly concerning modulation of neurotransmitter systems, HPA axis, and the synthesis of
neurotrophic factors. This leads to consider the chance that the combination of these different herbs may
produce potentially synergistic, mood-stabilizing efficacy, which remains to be investigated. Despite
a growing number of commercially available herbal formulations owning promising therapeutic
potential, most of them remain untested and none have been turned into registered drugs. To date,
there are many difficulties and obstacles in developing plant-derived medicines and this is due to an
inadequate knowledge of their mode of action, potential adverse reactions, contraindications, and
interactions with other drugs [173]. Thus, further studies are needed to deepen our understanding
and knowledge on both the safety profile and fine molecular mechanisms underlying the beneficial
effects of S. baicalensis, H. erinaceus and R. rosea in the brain. In fact, these herbal compounds
may also act through yet unexplored biological pathways that are implicated in both mood and
neurological disorders. For instance, some recent studies indicate that a variety of herbal compounds,
including S. baicalensis and R. rosea, may produce neuroprotective effects by modulating autophagy,
which is key to maintain intracellular homeostasis under oxidative stress conditions by degrading
abnormal proteins or organelles, especially mitochondria [174–177]. For instance, baicalin-induced
autophagy is associated with inhibition of the mitochondrial apoptotic pathway and protection
against experimental traumatic brain injury [178], while saliroside-induced autophagy counteracts
alpha-synuclein aggregation and toxicity [179]. The link among S. baicalensis, H. erinaceus, R. rosea
and autophagy has not been demonstrated in depressive disorders specifically. However, such
an issue deserves further investigation since autophagy alterations occur in both psychiatric and
neurodegenerative disorders, and autophagy modulation is bound to the mechanisms of action of
some conventional antidepressants and mood stabilizers [170,178–180].
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Abbreviations
6-OHDA 6-hydroxydopamine
AChE acetylcholinesterase
AD Alzheimer’s disease
APPL2 adaptor protein phosphotyrosine interacting with PH domain and leucine zipper 2
BBB blood-brain barrier
BDI Beck Depression Inventory
BDNF brain-derived neurotrophic factor
BZ benzodiazepine
CAT catalase
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CES-D Center for Epidemiologic Studies Depression Scale
CGI Clinical Global Impression
ChAT acetylcholine transporter
CORT corticosterone
COX-2 cyclooxygenase-2
CRF corticotrophin-releasing factor
CRH corticotropin-releasing hormone
CUMS chronic (unpredictable) mild stress
D1Rs DA D1 receptors
DA dopamine
DAT DA transporter
DCX doublecortin
DPPH 1-diphenyl-2-picrylhydrazyl
DST Direct Current Transcranial Stimulation
GABA Gamma-Aminobutyric acid
GABAAR GABA A subtype receptor
GAD generalized anxiety disorder
GR glucocorticoid receptor
GSH glutathione
GSH-Px glutathione peroxidase
GSK3β glycogen synthase kinase-3
H2O2 hydrogen peroxide
HAMD Hamilton Rating Scale for Depression
HARS Hamilton Anxiety Rating Scale
HD Huntington’s disease
HMBG1 High Mobility Group Box 1
HPA hypothalamic-pituitary-adrenal axis
HSP70 heat shock proteins 70
ICI Indefinite Complaints Index
IL-1β interleukin 1 beta
KMI Kupperman Menopausal Index
LC Locus Coeruleus
LPS Lipopolysaccharide
MAO A/B monoamine oxidase A/B
MDA malondialdehyde
METH methamphetamine
MMP mitochondrial membrane potential
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
NE norepinephrine
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
NGF nerve growth factor
NLRP3 nucleotide-binding domain, leucine-rich repeat, pyrin domain containing protein 3
NMDAR/NR2B N-methyl D-aspartate receptor subtype 2B
NPY neuropeptide Y
OBX olfactory bulbectomy
OSA obstructive sleep apnea
PCNA proliferating cell nuclear antigen
PD Parkinson’s disease
pERK phosphorylated Extracellular signal-regulated kinase
PGE(2) prostaglandin E(2)
pJNK phosphorylated c-Jun N-terminal kinases
PSD95 postsynaptic density protein-95
PSQI Pittsburgh Sleep Quality Index
ROS reactive oxygen species
RS repeated restraint stress
SAS self-rating anxiety scale
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SDS self-rating depression scale
SERM selective oestrogen receptor modulator
SOD superoxide dismutase
SYP synaptophysin
TLR4 toll-like receptor 4
TNF-α tumor necrosis factor alpha
TrkB tyrosine kinase receptor B
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